title: [Immune reconstitution syndrome related to a Mycobacterium avium complex infection, revealed by a mono-adenitis].
authors.affiliation: Service régional universitaire des maladies infectieuses et du voyageur, centre hospitalier Gustave-Dron, 135 rue du Président-Coty, Tourcoing, France. massongom@gmail.com
authors.forename: M
authors.initials: M
authors.lastname: Massongo
authors.forename: A
authors.initials: A
authors.lastname: Pasquet
authors.forename: T
authors.initials: T
authors.lastname: Huleux
authors.forename: E
authors.initials: E
authors.lastname: Aïssi
authors.forename: N
authors.initials: N
authors.lastname: Ettahar
authors.forename: Y
authors.initials: Y
authors.lastname: Yazdanpanah
authors.forename: H
authors.initials: H
authors.lastname: Melliez
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications*; D000038:Abscess / Q000209:etiology* / Q000601:surgery; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D000995:Antitubercular Agents / Q000627:therapeutic use; D001365:Axilla; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use; D000069454:Darunavir; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000627:therapeutic use; D000077560:Enfuvirtide; D004977:Ethambutol / Q000008:administration & dosage / Q000627:therapeutic use; D015700:HIV Envelope Protein gp41 / Q000008:administration & dosage / Q000627:therapeutic use; D015497:HIV-1; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000209:etiology*; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use; D008197:Lymph Node Excision; D008199:Lymphadenitis / Q000209:etiology* / Q000601:surgery; D008297:Male; D015270:Mycobacterium avium-intracellulare Infection / Q000150:complications* / Q000601:surgery; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use; D011718:Pyrazinamide / Q000008:administration & dosage / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D019438:Ritonavir / Q000008:administration & dosage / Q000627:therapeutic use; D013307:Streptomycin / Q000008:administration & dosage / Q000627:therapeutic use; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D000995:Antitubercular Agents; D017291:Clarithromycin; D000069454:Darunavir; D015224:Dideoxynucleosides; D000077560:Enfuvirtide; D004977:Ethambutol; D015700:HIV Envelope Protein gp41; D007538:Isoniazid; D019259:Lamivudine; D010446:Peptide Fragments; D011718:Pyrazinamide; D012293:Rifampin; D019438:Ritonavir; D013307:Streptomycin; D013449:Sulfonamides; D000099227:Abacavir